var data={"title":"Arsenic trioxide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Arsenic trioxide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5668?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=arsenic-trioxide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Arsenic trioxide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=arsenic-trioxide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Arsenic trioxide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708626\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Differentiation syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, weight gain or peripheral edema, hypotension, and renal, hepatic, or multiorgan dysfunction, in the presence or absence of leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. Temporary discontinuation of arsenic trioxide may be required.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">QT prolongation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Arsenic trioxide can cause QTc interval prolongation, complete atrioventricular block, and a torsade des pointes-type ventricular arrhythmia, which can be fatal. Before initiating therapy, assess the QTc interval, correct preexisting electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide to patients with ventricular arrhythmia or prolonged QTcF.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136731\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Trisenox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22781459\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Trisenox </li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136750\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136733\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Arsenic trioxide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute promyelocytic leukemia (APL), newly diagnosed, low-risk:</b> IV: <b>Note:</b> Prophylaxis for differentiation syndrome with prednisone 0.5 mg/kg/day is recommended starting on day 1 and continuing until the end of induction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction (1 cycle):</i> 0.15 mg/kg once daily (in combination with tretinoin); continue until bone marrow remission, not to exceed 60 days (Lo-Coco 2013; Platzbecker 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Consolidation (4 cycles):</i> 0.15 mg/kg once daily for 5 days each week during weeks 1 to 4 of each 8-week consolidation cycle (in combination with tretinoin) for a total of 4 consolidation cycles (Lo-Coco 2013; Platzbecker 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>APL (newly diagnosed, including intermediate- and/or high-risk disease) (off-label):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>APL0406 protocol: </i>\n      <i>Intermediate-</i>\n      <i>risk (Lo-Coco 2013; Platzbecker 2017):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction (1 cycle):</i> 0.15 mg/kg once daily (in combination with tretinoin); continue until bone marrow remission, not to exceed 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation (4 cycles):</i> 0.15 mg/kg once daily for 5 days each week during weeks 1 to 4 of each 8-week consolidation cycle (in combination with tretinoin) for a total of 4 consolidation cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>AML17 protocol </i>\n      <i>(low-, intermediate-, or high-risk); in combination with tretinoin (Burnett 2015):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction (cycle 1):</i> 0.3 mg/kg once daily on days 1 to 5 in week 1, followed by 0.25 mg/kg twice a week during weeks 2 to 8; high-risk patients were also administered a single dose of gemtuzumab within the first 4 days of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation (cycles 2 to 5):</i> 0.3 mg/kg once daily on days 1 to 5 in week 1, followed by 0.25 mg/kg twice a week during weeks 2 to 4</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>C9710 protocol (low-, intermediate-, or high-risk); following remission induction with tretinoin, daunorubicin, and cytarabine, and followed by tretinoin (Powell 2010):</i> Consolidation (2 courses): 0.15 mg/kg once daily on days 1 to 5 in each week during weeks 1 to 5; each course is separated by 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low-, intermediate-, or high-risk patients unable to tolerate anthracycline-based therapy; in combination with tretinoin (Estey 2006; Ravandi 2009):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction (1 cycle; beginning 10 days after initiation of tretinoin):</i> 0.15 mg/kg once daily until bone marrow remission; maximum: 75 doses for induction; high-risk patients were also administered gemtuzumab on day 1 of induction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation (4 cycles):</i> 0.15 mg/kg once daily on Monday through Friday for 4 weeks of every 8-week treatment cycle for 4 cycles (weeks 1 to 4, 9 to 12, 17 to 20, and 25 to 28)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>APML4 protocol (low-, intermediate- and high-risk) (Iland 2012):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction (1 cycle):</i> 0.15 mg/kg once daily on days 9 to 36 (in combination with tretinoin and age-adjusted idarubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation (2 cycles):</i> 0.15 mg/kg once daily on days 1 to 28 of consolidation cycle 1 (in combination with tretinoin); 0.15 mg/kg once daily on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, and 29 to 33 of consolidation cycle 2 (in combination with tretinoin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>APL (relapsed or refractory):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction (1 cycle):</i> 0.15 mg/kg once daily until bone marrow remission; maximum: 60 doses for induction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Consolidation (1 cycle):</i> 0.15 mg/kg once daily for 25 doses over a period of up to 5 weeks, beginning 3 to 6 weeks after completion of induction therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136746\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=arsenic-trioxide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Arsenic trioxide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Arsenic trioxide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute promyelocytic leukemia (APL), relapsed or refractory:</b> Children &ge;4 years of age: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction (1 cycle):</i> 0.15 mg/kg once daily until bone marrow remission; maximum: 60 doses for induction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Consolidation (1 cycle):</i> 0.15 mg/kg once daily for 25 doses over a period of up to 5 weeks, beginning 3 to 6 weeks after completion of induction therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>APL, newly diagnosed (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction, consolidation, and maintenance (Mathews 2006):</i> Children &ge;3 years of age and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction:</i> 0.15 mg/kg once daily (maximum dose: 10 mg); administer daily until bone marrow remission; maximum: 60 doses for induction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation:</i> 0.15 mg/kg once daily (maximum dose: 10 mg) for 4 weeks, starting 4 weeks after completion of induction therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance:</i> 0.15 mg/kg once daily (maximum dose: 10 mg) administered 10 days per month for 6 months, starting 4 weeks after completion of consolidation therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>APML4 protocol (Iland 2012): Low-, intermediate-, and high-risk: </i>Children &ge;3 years of age and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction:</i> 0.15 mg/kg once daily on days 9 to 36 (in combination with tretinoin and idarubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation (2 cycles):</i> 0.15 mg/kg once daily on days 1 to 28 of consolidation cycle 1 (in combination with tretinoin); 0.15 mg/kg/day on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, and 29 to 33 of consolidation cycle 2 (in combination with tretinoin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low-</i> <i>risk; in combination with tretinoin (Ravandi 2009): </i>Adolescents &ge;14 years of age:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Induction (1 cycle; beginning 10 days after initiation of tretinoin):</i> 0.15 mg/kg once daily until bone marrow remission; maximum: 75 doses for induction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Consolidation (4 cycles):</i> 0.15 mg/kg once daily on Monday through Friday for 4 weeks of every 8-week treatment cycle for 4 cycles (weeks 1 to 4, 9 to 12, 17 to 20, and 25 to 28)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136735\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: Use with caution (systemic exposure to metabolites may be higher); may require dosage reduction; monitor closely for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136736\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Patients with severe impairment (Child-Pugh class C) should be monitored closely for toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28357366\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage reduction levels (for hematologic and nonhematologic toxicities; tretinoin may also require dose reduction):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial dosage: 0.15 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First dose reduction level: 0.11 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second dose reduction level: 0.1 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Third dose reduction level: 0.075 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment when used alone or in combination with tretinoin: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Hematologic toxicities:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Leukocytosis (WBC &gt;10,000/mm<sup>3</sup></i>\n      <i>):</i> Administer hydroxyurea; may discontinue hydroxyurea when WBC declines to &lt;10,000/mm<i><sup>3</sup>. </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>ANC &lt;1,000/mm<sup>3</sup>: </i>Consider reducing the dose (arsenic trioxide and tretinoin) by 1 dose level. If myelosuppression lasts &ge;50 days or occurs on 2 consecutive cycles, assess marrow aspirate for remission status. In the case of molecular remission, resume arsenic trioxide (and tretinoin) at 1 dose level lower.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Platelets &lt;50,000/mm<sup>3</sup>: </i>Consider reducing the dose (arsenic trioxide and tretinoin) by 1 dose level. If myelosuppression lasts &ge;50 days or occurs on 2 consecutive cycles, assess marrow aspirate for remission status. In the case of molecular remission, resume arsenic trioxide (and tretinoin) at 1 dose level lower.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Nonhematologic toxicities: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Differentiation syndrome (defined as the presence of 2 or more of the following: Unexplained fever, dyspnea, pleural and/or pericardial effusion, pulmonary infiltrates, renal failure, hypotension, weight gain &gt;5 kg):</i> Temporarily withhold arsenic trioxide (consider withholding tretinoin if severe) and begin dexamethasone 10 mg IV every 12 hours until resolution of signs/symptoms for a minimum of 3 days. When clinical condition improves, resume treatment with the dose of the withheld drug(s) reduced by 50%. After 7 days, in the absence of recurrent symptoms, increase the dose to the recommended dosage. If symptoms recur, decrease arsenic and/or tretinoin to the previous dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hepatotoxicity during treatment </i>\n      <i>(defined as 1 or more of the following: total bilirubin &gt;3 times the upper limit of normal (ULN), AST &gt;5 times ULN, alkaline phosphatase &gt;5 times ULN):</i> Withhold arsenic trioxide and/or tretinoin. When total bilirubin &lt;1.5 times ULN and AST/alkaline phosphatase &lt;3 times ULN, resume treatment with the dose(s) reduced by 50%. After 7 days at the reduced dose(s), in the absence of worsening hepatotoxicity, increase the dose(s) back to the recommended dose(s). If hepatotoxicity recurs, discontinue permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Q<i>T<sub>c</sub> prolongation &gt;450 msec (for males) or &gt;460 msec (for females): </i>Withhold arsenic trioxide and any medication know to prolong the QTc interval. Replete electrolytes. After the QTc normalizes, resume arsenic trioxide with a 50% dose reduction (to 0.075 mg/kg once daily) for 7 days. If the 50% dose reduction is tolerated for 7 days, in the absence of QTc prolongation, increase the arsenic trioxide dose to 0.11 mg/kg once daily for 7 days. In the absence of QTc prolongation, the dose may be further increased to 0.15 mg/kg once daily during the 14-day dose escalation period.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Other nonhematologic reactions:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Moderate (grade 2): </i>Reduce the dose (arsenic trioxide and/or tretinoin) by 1 dose level.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Severe or life-threatening (grade 3 or 4): </i>Temporarily withhold arsenic trioxide and tretinoin. When the adverse reaction resolves to no more than mild (grade 1), resume arsenic trioxide and tretinoin with the dose reduced by 2 dose levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136716\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trisenox: 10 mg/10 mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trisenox: 12 mg/6 mL (6 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136702\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136718\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 2 hours. If acute vasomotor reactions occur, the infusion duration may be extended to up to 4 hours. Arsenic trioxide does not require administration via a central venous catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arsenic trioxide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130882\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136717\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute promyelocytic leukemia (newly diagnosed) (low-risk disease):</b> Treatment of newly diagnosed low-risk acute promyelocytic leukemia (APL), in combination with tretinoin, in adults whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute promyelocytic leukemia (relapsed or refractory):</b> Remission induction and consolidation treatment of APL in patients who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721879\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute promyelocytic leukemia (newly diagnosed) (including intermediate- or high-risk disease) (adults); Acute promyelocytic leukemia (newly diagnosed) (pediatrics)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401582\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Multiple concentrations: Arsenic trioxide is available in different concentrations; verify concentration prior to admixture to assure appropriate dose preparation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136708\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (55%), edema (40%), prolonged Q-T interval on ECG (40%; &gt;500 msec), chest pain (25%), hypotension (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (63%), headache (60%), insomnia (43%), rigors (38%), paresthesia (33%), anxiety (30%), dizziness (23%), depression (20%), pain (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis (43%), pruritus (33%), xeroderma (15%), diaphoresis (13%), erythema (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (50%), hyperglycemia (45%), hypomagnesemia (45%), hyperkalemia (18%), weight gain (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (75%), abdominal pain (58%), vomiting (58%), diarrhea (53%), sore throat (35%), constipation (28%), anorexia (23%), decreased appetite (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginal hemorrhage (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukocytosis (50%; grades 3/4: 3%), APL differentiation syndrome (16% to 23%; grades 3/4: 8%), anemia (20%; grades 3/4: 5%), bruise (20%), thrombocytopenia (18%; grades 3/4: 13%), febrile neutropenia (13%; grades 3/4: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (20%), increased serum AST (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes simplex infection (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (20%), erythema at injection site (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (33%), myalgia (25%), ostealgia (23%), back pain (18%), limb pain (13%), neck pain (13%), tremor (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (65%), dyspnea (53%), epistaxis (25%), hypoxia (23%), pleural effusion (20%), sinusitis (20%), post nasal drip (13%), upper respiratory tract infection (13%), wheezing (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (63%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (10%), flushing (10%), palpitations (10%), ECG abnormality (8%; non-QT prolongation), facial edema (8%), atrial arrhythmia (5%), torsades de pointes (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (8%), seizure (8%), agitation (5%), coma (5%), confusion (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pallor (10%), hyperpigmentation (8%), night sweats (8%), skin lesion (8%), urticaria (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (10%), hypoglycemia (8%), intermenstrual bleeding (8%), weight loss (8%), acidosis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (10%), loose stools (10%), abdominal distension (8%), abdominal tenderness (8%), bloody diarrhea (8%), fecal incontinence (8%), gastrointestinal hemorrhage (8%), oral bullae (8%), xerostomia (8%), oral candidiasis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Oliguria (5%), urinary incontinence (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (10%; grades 3/4: 10%), disseminated intravascular coagulation (8%; grades 3/4: 8%), hemorrhage (8%), hyperleukocytosis (grades 3/4: 8%), lymphadenopathy (8%), petechia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Bacterial infection (8%), herpes zoster (8%), sepsis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Swelling at injection site (10%), local skin exfoliation (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (10%), eye irritation (10%), xerophthalmia (8%), eye redness (with pain: 5%), eyelid edema (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (8%), tinnitus (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (8%), renal insufficiency (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Abnormal breath sounds (decreased: 10%), rales (10%), hemoptysis (8%), rhonchi (8%), tachypnea (8%), nasopharyngitis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Atrioventricular block, bone marrow necrosis, cardiac failure, deafness, heart block, increased gamma-glutamyl transferase, malignant melanoma, pancytopenia, paresis, peripheral neuropathy, rhabdomyolysis, squamous cell carcinoma, toxic epidermal necrolysis, ventricular premature contractions, ventricular tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136721\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to arsenic or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Pregnancy; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136706\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Differentiation syndrome: <b>[US Boxed Warning]: </b><b>Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide have experienced symptoms of differentiation syndrome (may be fatal if not treated). Symptoms may include fever (unexplained), dyspnea, acute respiratory distress, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, weight gain or peripheral edema, hypotension, and renal, hepatic, or multiorgan dysfunction, occurring with or without leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until signs/symptoms resolve. May require temporary discontinuation of arsenic trioxide. </b>The onset of differentiation syndrome has occurred as early as day 1 of induction to as late as the second month of induction therapy. Prophylaxis with prednisone is recommended when arsenic trioxide is used in combination with tretinoin. At the first signs of differentiation syndrome, interrupt arsenic trioxide and administer dexamethasone 10 mg IV twice daily; continue high-dose corticosteroids until signs/symptoms have abated for at least 3 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Arsenic trioxide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: In newly diagnosed low-risk APL studies, patients treated with arsenic trioxide in combination with tretinoin experienced elevated AST, alkaline phosphatase, and/or serum bilirubin, which usually resolved with temporary discontinuation of arsenic trioxide and/or tretinoin. Monitor LFTs at least 2 to 3 times a week during arsenic trioxide treatment and continue monitoring until toxicity recovers. Withhold arsenic trioxide treatment and/or tretinoin if AST, alkaline phosphatase, and/or serum bilirubin elevations &gt;5 times the ULN occur. Long-term hepatic abnormalities may occur in patients with APL treated with arsenic trioxide in combination with tretinoin. Mild hepatic dysfunction and hepatic steatosis have been observed at a median of 7 years (range: up to 14 years) following arsenic trioxide and tretinoin combination therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: <b>[US Boxed Warning]: Arsenic trioxide may cause QTc interval prolongation, atrioventricular block, and a torsade des pointes-type ventricular arrhythmia, which may be fatal. </b><b>Prior to treatment initiation, assess the QTc interval (by ECG), correct preexisting electrolyte abnormalities, and consider discontinuing medications known to prolong QTc interval. Do not administer arsenic trioxide to patients with ventricular arrhythmia or prolonged QTcF. </b>In newly diagnosed low-risk APL studies, some patients who received arsenic trioxide in combination with tretinoin experienced QTc prolongation &gt;450 msec (for males) and &gt;460 msec (for females) throughout treatment cycles. In studies for relapsed or refractory APL, over one-third of patients who received arsenic trioxide (as monotherapy) had at least one ECG with a QTc interval &gt;500 msec. Prolonged QTc has been observed between 1 and 5 weeks after start of arsenic trioxide treatment, and usually resolved by 8 weeks after treatment. There are no data on the effect of arsenic trioxide on the QTc interval during the infusion. The risk of torsades de pointes is related to the extent of QTc prolongation, concurrent use of QTc prolonging medications, a history of torsade des pointes, preexisting QTc interval prolongation, heart failure, concurrent potassium-wasting diuretics, or other conditions associated with hypokalemia or hypomagnesemia. The risk may be increased when arsenic trioxide is coadministered with medications associated with electrolyte abnormalities (eg, diuretics or amphotericin B). If it is not possible to discontinue concomitant medications associated with QTc prolongation, perform cardiac monitoring frequently. Maintain serum potassium &gt;4 mEq/L and magnesium &gt;1.8 mg/dL during treatment. Monitor ECG weekly (more frequently in clinically unstable patients). If QTc &gt;500 msec develops, immediately withhold arsenic trioxide treatment and any medication known to prolong the QTc interval and correct electrolyte abnormalities; when the QTc normalizes, resume arsenic trioxide at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Arsenic trioxide is a human carcinogen; monitor for the development of second primary malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor closely for toxicity in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment (dose reduction may be warranted); systemic exposure may be higher; monitor closely for toxicities. Arsenic trioxide has not been studied in dialysis patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple concentrations: Arsenic trioxide is available in different concentrations; verify concentration prior to admixture to assure appropriate dose preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298770\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136710\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8977&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136723\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on the mechanism of action and findings in animal reproduction studies, arsenic may cause fetal harm if administered during pregnancy. Arsenic crosses the human placenta. In studies of women exposed to high levels of arsenic from drinking water, cord blood levels were similar to maternal serum levels. Dimethylarsinic acid (DMA) was the form of arsenic found in the fetus. An increased risk of low birth weight and still births were observed in women who ingested high levels of dietary arsenic. Verify pregnancy status in females of reproductive potential prior to initiating therapy. Females of reproductive potential should use effective contraception during treatment and for 6 months after the final arsenic trioxide dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final arsenic trioxide dose. An international consensus panel has published guidelines for the management of hematologic malignancies during pregnancy; arsenic trioxide is teratogenic and should not be used throughout pregnancy (Lishner 2016). Arsenic trioxide may impair fertility in males of reproductive potential (based on findings in animal studies).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5132460\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Arsenic is naturally found in breast milk; concentrations range from 0.2 to 6 mcg/kg. In studies of women exposed to high levels of arsenic from drinking water, breast milk concentrations were low (~3.1 mcg/kg) and did not correlate with maternal serum levels. The possible effect of maternal arsenic trioxide therapy on breast milk concentrations is not known. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during therapy and for 2 weeks after the final arsenic trioxide dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136714\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor electrolytes (potassium, calcium, and magnesium), CBC with differential, renal function (serum creatinine), hepatic function, blood glucose, and coagulation parameters at baseline then at least 2 to 3 times a week during induction and at least weekly during consolidation; more frequent monitoring may be necessary in unstable patients; pregnancy test (prior to treatment in females of reproductive potential); baseline then weekly 12-lead ECG; signs/symptoms of APL differentiation syndrome (unexplained fever, dyspnea, and/or weight gain, abnormal chest auscultatory findings or radiographic abnormalities).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136705\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Arsenic trioxide induces apoptosis in APL cells via morphological changes and DNA fragmentation; also damages or degrades the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR) alpha</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136720\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Arsenious acid (As<sup>III</sup>): 562 L; widely distributed throughout body tissues; dependent on body weight and increases as body weight increases; orally administered arsenic trioxide distributes into the CNS</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Arsenic trioxide is immediately hydrolyzed to the active form, arsenious acid (As<sup>III</sup>) which is methylated (hepatically) to the less active pentavalent metabolites, monomethylarsonic acid (MMA<sup>v</sup>) and dimethylarsinic acid (DMA<sup>v</sup>) by methyltransferases; As<sup>III</sup> is also oxidized to the minor metabolite, arsenic acid (As<sup>v</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: As<sup>III</sup>: 10 to 14 hours; MMA<sup>v</sup>: ~32 hours; DMA<sup>v</sup>: ~72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: As<sup>III</sup>: At the end of infusion (2 hours); MMA<sup>v</sup> and DMA<sup>v</sup>; ~10 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (MMA<sup>v</sup>, DMA<sup>v</sup>, and ~15% of a dose as unchanged As<sup>III</sup>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323000\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Trisenox Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/6 mL (6 mL): $1,069.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539820\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Asadin (MY, TW);</li>\n      <li>Phenasen (AU);</li>\n      <li>Trisenox (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IL, IT, JP, KR, LT, LU, MT, NL, NO, PL, PT, RO, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26384238\"></a>Burnett AK, Russell NH, Hills RK, et al; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. <i>Lancet Oncol</i>. 2015;16(13):1295-1305. doi: 10.1016/S1470-2045(15)00193-X.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/26384238/pubmed\" target=\"_blank\" id=\"26384238\">26384238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Concha G, Vogler G, Lezcano D, Nermell B, Vahter M. Exposure to inorganic arsenic metabolites during early human development. <i>Toxicol Sci</i>. 1998;44(2):185-190. doi: 10.1006/toxs.1998.2486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/9742656/pubmed\" target=\"_blank\" id=\"9742656\">9742656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082. doi: 10.1002/pbc.24508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198. doi: 10.1002/pbc.23114.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16373661\"></a>Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i>. 2006;107(9):3469-3473. doi: 10.1182/blood-2005-10-4006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/16373661/pubmed\" target=\"_blank\" id=\"16373661\">16373661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22715121\"></a>Iland HJ, Bradstock K, Supple SG, et al; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). <i>Blood</i>. 2012;120(8):1570-1580. doi: 10.1182/blood-2012-02-410746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/22715121/pubmed\" target=\"_blank\" id=\"22715121\">22715121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press; 2001, 162-184.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26628463\"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol.</i> 2016;34(5):501-508. doi: 10.1200/JCO.2015.62.4445.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/26628463/pubmed\" target=\"_blank\" id=\"26628463\">26628463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23841729\"></a>Lo-Coco F, Avvisati G, Vignetti M, et al; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. <i>N Engl J Med</i>. 2013;369(2):111-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/23841729/pubmed\" target=\"_blank\" id=\"23841729\">23841729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16352810\"></a>Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. <i>Blood</i>. 2006;107(7):2627-2632. doi: 10.1182/blood-2005-08-3532.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/16352810/pubmed\" target=\"_blank\" id=\"16352810\">16352810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27400939\"></a>Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. <i>J Clin Oncol</i>. 2017;35(6):605-612. doi: 10.1200/JCO.2016.67.1982.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/27400939/pubmed\" target=\"_blank\" id=\"27400939\">27400939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20705755\"></a>Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i>. 2010;116(19):3751-3757. doi: 10.1182/blood-2010-02-269621.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/20705755/pubmed\" target=\"_blank\" id=\"20705755\">20705755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19075265\"></a>Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. <i>J Clin Oncol</i>. 2009;27(4):504-510. doi: 10.1200/JCO.2008.18.6130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/19075265/pubmed\" target=\"_blank\" id=\"19075265\">19075265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trisenox (arsenic trioxide) [prescribing information]. North Wales, PA: Teva Pharmaceuticals; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trisenox (arsenic trioxide) [product monograph]. Montreal, Quebec, Canada: Teva Canada Innovation; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16524957\"></a>von Ehrenstein OS, Guha Mazumder DN, Hira-Smith M, et al. Pregnancy outcomes, infant mortality, and arsenic in drinking water in West Bengal, India. <i>Am J Epidemiol</i>. 2006;163(7):662-669.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/16651647/pubmed\" target=\"_blank\" id=\"16651647\">16651647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12550085\"></a>Yang CY, Chang CC, Tsai SS, Chuang HY, Ho CK, Wu TN. Arsenic in drinking water and adverse pregnancy outcome in an arseniasis-endemic area in northeastern Taiwan. <i>Environ Res</i>. 2003;91(1):29-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arsenic-trioxide-drug-information/abstract-text/12550085/pubmed\" target=\"_blank\" id=\"12550085\">12550085</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8977 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708626\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F136731\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F22781459\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F136750\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F136733\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F136746\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F136735\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F136736\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F28357366\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136716\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F136702\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F136718\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130882\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F136717\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721879\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401582\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136708\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136721\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136706\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298770\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136710\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136723\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5132460\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F136714\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136705\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F136720\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323000\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539820\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8977|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=arsenic-trioxide-patient-drug-information\" class=\"drug drug_patient\">Arsenic trioxide: Patient drug information</a></li><li><a href=\"topic.htm?path=arsenic-trioxide-pediatric-drug-information\" class=\"drug drug_pediatric\">Arsenic trioxide: Pediatric drug information</a></li></ul></div></div>","javascript":null}